Brain Sciences最新文献

{"title":"Effects of Probiotic Supplementation on Depressive Symptoms, Sleep Quality, and Modulation of Gut Microbiota and Inflammatory Biomarkers: A Randomized Controlled Trial.","authors":"S Rehan Ahmad, Abdullah M AlShahrani, Anupriya Kumari","doi":"10.3390/brainsci15070761","DOIUrl":"10.3390/brainsci15070761","url":null,"abstract":"<p><p><b>Background:</b> More than merely determining our sleep pattern, our body's internal clock also improves the quality of our sleep, alleviates the symptoms of depression, and maintains the balance of our gut flora. <b>Methods:</b> We carried out a 12-week randomized controlled trial with 99 adults from Kolkata, New Delhi, and Pune who reported sleep problems and symptoms of depression or anxiety. Participants received either a probiotic formulated to improve sleep quality and reduce depressive symptoms or a placebo. We tracked sleep using overnight studies and wearable devices, assessed depressive symptoms with standardized questionnaires, and analyzed stool samples to profile gut bacteria and their metabolites using gene sequencing and metabolomics. Advanced statistics and machine learning helped us pinpoint the key microbial and metabolic factors tied to sleep and mental health. <b>Results:</b> At the start, participants with disrupted sleep and depressive symptoms had fewer beneficial gut bacteria like <i>Bifidobacterium</i> and <i>Lactobacillus</i>, more inflammation-related microbes, and lower levels of helpful short-chain fatty acids. These imbalances were linked to poorer sleep efficiency, less REM sleep, and higher depression and anxiety scores. After 12 weeks, those taking the circadian-supporting probiotic saw a statistically significant increase in beneficial gut bacteria, improved sleep efficiency (+7.4%, <i>p</i> = 0.02), and greater reductions in depression and anxiety compared to the placebo. Increases in SCFA-producing bacteria most strongly predicted improvements. <b>Conclusions:</b> Our results show that taking a probiotic supplement can help bring your gut back into balance, support better sleep, and lift symptoms of depression and anxiety. This offers a hopeful and practical option for people looking for real relief from these deeply connected challenges.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Cortical Activations Among Young Adults Who Fall Versus Those Who Recover Successfully Following an Unexpected Slip During Walking.","authors":"Rudri Purohit, Shuaijie Wang, Tanvi Bhatt","doi":"10.3390/brainsci15070765","DOIUrl":"10.3390/brainsci15070765","url":null,"abstract":"<p><p><b>Background:</b> Biomechanical and neuromuscular differences between falls and recoveries have been well-studied; however, the cortical correlations remain unclear. Using mobile brain imaging via electroencephalography (EEG), we examined differences in sensorimotor beta frequencies between falls and recoveries during an unpredicted slip in walking. <b>Methods</b>: We recruited 22 young adults (15 female; 18-35 years) who experienced a slip (65 cm) during walking. Raw EEG signals were band-pass filtered, and independent component analysis was performed to remove non-neural sources, eventually three participants were excluded due to excessive artifacts. Peak beta power was extracted from three time-bins: 400 milliseconds pre-, 0-150 milliseconds post and 150-300 milliseconds post-perturbation from the midline (Cz) electrode. A 2 × 3 Analysis of Covariance assessed the interaction between time-bins and group on beta power, followed by Independent and Paired <i>t</i>-tests for between and within-group post hoc comparisons. <b>Results:</b> All participants (<i>n</i> = 19) experienced a balance loss, seven experienced a fall. There was a time × group interaction on beta power <i>(p</i> < 0.05). With no group differences pre-perturbation, participants who experienced a fall exhibited higher beta power during 0-150 milliseconds post-perturbation than those who recovered <i>(p</i> < 0.001). However, there were no group differences in beta power during 150-300 milliseconds post-perturbation. <b>Conclusions</b>: Young adults exhibiting a greater increase in beta power during the early post-perturbation period experienced a fall, suggesting a higher cortical error detection due to a larger mismatch in the expected and ongoing postural state and greater cortical dependence for sensorimotor processing. Our study results provide an overview of the possible cortical governance to modulate slip-fall/recovery outcomes.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Multimodal Rehabilitation of Complex Regional Pain Syndrome and Its Contribution to the Improvement of Visual-Spatial Memory, Visual Information-Processing Speed, Mood, and Coping with Pain-A Nonrandomized Controlled Trial.","authors":"Justyna Wiśniowska, Iana Andreieva, Dominika Robak, Natalia Salata, Beata Tarnacka","doi":"10.3390/brainsci15070763","DOIUrl":"10.3390/brainsci15070763","url":null,"abstract":"<p><p><b>Objectives</b>: To investigate whether a Multimodal Rehabilitation Program (MRP) affects the change in visual-spatial abilities, especially attention, information-processing speed, visual-spatial learning, the severity of depression, and strategies for coping with pain in Complex Regional Pain Syndrome (CRPS) participants. <b>Methods</b>: The study was conducted between October 2021 and February 2023, with a 4-week rehabilitation program that included individual physiotherapy, manual and physical therapy, and psychological intervention such as psychoeducation, relaxation, and Graded Motor Imagery therapy. Twenty participants with CRPS and twenty healthy participants, forming a control group, were enlisted. The study was a 2-arm parallel: a CRPS group with MRP intervention and a healthy control group matched to the CRPS group according to demographic variables. Before and after, the MRP participants in the CRPS group were assessed for visual-spatial learning, attention abilities, severity of depression, and pain-coping strategy. The healthy control group underwent the same assessment without intervention before two measurements. The primary outcome measure was Reproduction on Rey-Osterrieth's Complex Figure Test assessing visual-spatial learning. <b>Results</b>: In the post-test compared to the pre-test, the participants with CRPS obtained a significantly high score in visual-spatial learning (<i>p</i> < 0.01) and visual information-processing speed (<i>p</i> = 0.01). They made significantly fewer omission mistakes in visual working memory (<i>p</i> = 0.01). After the MRP compared to the pre-test, the CRPS participants indicated a decrease in the severity of depression (<i>p</i> = 0.04) and used a task-oriented strategy for coping with pain more often than before the rehabilitation program (<i>p</i> = 0.02). <b>Conclusions</b>: After a 4-week MRP, the following outcomes were obtained: an increase in visual-spatial learning, visual information-processing speed, a decrease in severity of depression, and a change in the pain-coping strategies-which became more adaptive.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Health and Quality of Life in Patients with Untreated Unruptured Intracranial Aneurysms: A Systematic Review and Meta-Analysis of 417,152 Patients with Trial Sequential Analysis.","authors":"Plamen Penchev, Kiril Ivanov, Daniela Milanova-Ilieva, Lyubomir Gaydarski, Kiril Kostov, Nikola Boyadzhiev, Petar-Preslav Petrov, Patrice Mehandzhiev, Remzi Hyusein, Vladislav Velchev, Ilko Ilyov, Valentin Kuzmanov, Gergana Dzhikova, Desislava Dobreva, Liliana Toptchiyska, Vasilena Dimitrova, Victoria Petrova, Svetoslav Yorov, Pavel Stanchev, Martin Gyulbaharov, Noor Husain, Nikolai Ramadanov","doi":"10.3390/brainsci15070764","DOIUrl":"10.3390/brainsci15070764","url":null,"abstract":"<p><p><b>Introduction:</b> Unruptured intracranial aneurysms (UIAs) can induce psychological stress, leading to anxiety, depression, and impaired quality of life (QoL). Most studies on this topic are limited by small sample sizes, cross-sectional designs, and a focus on treated rather than untreated cases, leaving a gap in the literature. We aimed to conduct a systematic review and meta-analysis to evaluate mental health and QoL outcomes in patients with untreated UIAs. <b>Methods:</b> A systematic search was conducted up to 30 November 2024 using PubMed, Scopus, and Cochrane Central for studies comparing patients with untreated UIAs to a control group. The outcomes of interest included anxiety, depression, and QoL. Statistical analysis was performed using RevMan 5.1.7 and R 4.3.1. Heterogeneity was assessed using I² statistics and the Cochrane Q test. Risk ratios (RR) and standardized mean differences (SMD) were computed using a frequentist random-effects model. <b>Results:</b> We included five studies with 417,152 patients, of whom 85,668 (20.53%) had untreated UIAs. In the pooled analysis, patients with untreated UIAs had significantly higher anxiety levels (SMD 0.66; 95% CI [0.16; 1.17]; <i>p</i> = 0.01; I² = 76%) and lower QoL (SMD -0.82; 95% CI [-1.12; -0.53]; <i>p</i> = 0.01; I² = 56%) compared to the control group However, no statistically significant differences were found in depression (RR 0.94; 95% CI [0.52; 1.72]; <i>p</i> = 0.84; I² = 88%) between groups. <b>Conclusions:</b> This meta-analysis indicates a potential association between untreated UIAs and increased anxiety levels and reduced QoL. Regarding depression, no significant differences were observed between groups.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting CX3CR1 Signaling Dynamics: A Critical Determinant in the Temporal Regulation of Post-Stroke Neurorepair.","authors":"Quan He, Tong Zhou, Quanwei He","doi":"10.3390/brainsci15070759","DOIUrl":"10.3390/brainsci15070759","url":null,"abstract":"<p><p>Ischemic stroke ranks among the top global causes of disability and mortality, with a highly dynamic pathological process. Post-stroke neuroinflammation, mediated by microglia, demonstrates a dual role in both injury and repair. The CX3CR1/CX3CL1 signaling axis, highly expressed in microglia, acts as a key regulator. This review examines the spatiotemporal dynamics of the axis across the stroke process and its involvement in neural repair. Crucially, this signaling pathway demonstrates stage-dependent functional duality: its cellular sources, receptor expression profiles, and functional consequences undergo temporally orchestrated shifts, manifesting coexisting or interconverting protective and damaging properties. Ignoring this dynamism compromises the therapeutic efficacy of targeted interventions. Thus, we propose a triple precision strategy of \"stroke phase-biomarker-targeted intervention\". It uses specific biomarkers for precise staging and designs interventions based on each phase's signaling characteristics. Despite challenges like biomarker validation, mechanistic exploration, and cross-species differences, integrating cutting-edge technologies such as spatial metabolomics and AI-driven dynamic modeling promises to shift stroke therapy toward personalized spatiotemporal programming. Temporally targeting CX3CR1 signaling may offer a key basis for developing next-generation precision neural repair strategies for stroke.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom-Triggered Alcohol Detoxification Compared to Fixed-Dose Regimen of Benzodiazepines: A Retrospective Case-Control Study.","authors":"Laurent Becciolini, Fabienne Wehrli, Jens Kronschnabel, Carolina Wiesendanger, Norbert Scherbaum, Patrik Roser","doi":"10.3390/brainsci15070758","DOIUrl":"10.3390/brainsci15070758","url":null,"abstract":"<p><strong>Background: </strong>Alcohol withdrawal syndrome is a common clinical challenge that may lead to significant complications if not properly managed. Symptom-triggered therapy (STT) represents a promising alternative to fixed-dose regimens (FDRs) providing benzodiazepine prescriptions based on objectively quantified withdrawal symptoms. This study aimed to evaluate the effectiveness and safety of STT using the Hamburg Alcohol Withdrawal Scale (HAES) compared to FDRs in the management of inpatient alcohol detoxification.</p><p><strong>Methods: </strong>In a retrospective case-control study, alcohol detoxification treatment in STT was compared with FDRs. During a twelve-month observation period, a total of 123 patients in the STT group were recruited and compared with 123 controls in the FDR group (matched according to sex, age, and current amount of alcohol consumption) treated in the same hospital before the implementation of STT. The study outcomes included the total benzodiazepine dosage, duration of acute detoxification phase, length of inpatient stay, and occurrence of complications such as epileptic seizures and delirium tremens.</p><p><strong>Results: </strong>STT showed a significantly lower total benzodiazepine dosage (22.50 mg vs. 115.00 mg, <i>p</i> < 0.001), a shorter duration of the detoxification phase (48.00 h vs. 201.75 h, <i>p</i> < 0.001), and a reduced length of inpatient stay (23.00 days vs. 28.00 days, <i>p</i> = 0.003) compared to FDRs. There were no significant differences in the rates of complications between the two settings. Linear mixed model analysis revealed that the differences remained highly significant even after adjusting for various explanatory variables (i.e., age, sex, standard units of alcohol, psychiatric comorbidities, treatment discontinuation, and occurrence of any complication).</p><p><strong>Conclusions: </strong>STT appears to be as effective and safe as traditional fixed-dose regimens of benzodiazepines for the management of inpatient alcohol detoxification. This approach may thereby minimize unnecessary pharmacological exposure, facilitate the earlier integration of patients into psychoeducational and psychosocial interventions, and reduce healthcare costs.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals.","authors":"Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel Angel Alvarez-Mon, Miguel A Ortega, Melchor Alvarez-Mon, Javier Quintero","doi":"10.3390/brainsci15070757","DOIUrl":"10.3390/brainsci15070757","url":null,"abstract":"<p><strong>Background and objectives: </strong>Duloxetine is widely used for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and various types of neuropathic pain. While its efficacy is well documented in clinical trials, less is known about how it is perceived and utilized in routine psychiatric practice. To address this knowledge gap, we conducted a cross-sectional observational study involving 80 psychiatrists from Spain to assess real-world clinical attitudes toward duloxetine.</p><p><strong>Methods: </strong>Participants completed a 20-item multiple-choice questionnaire that examined familiarity, perceived efficacy in multiple conditions (MDD, GAD, neuropathic pain, somatization, and quality of life), and perspectives on tolerability, safety, adherence, and overall satisfaction.</p><p><strong>Results: </strong>Survey results indicated that a large majority of psychiatrists frequently prescribe duloxetine, particularly for patients with MDD and comorbid chronic pain. Notably, 94% rated it as either \"more effective\" or \"much more effective\" for diabetic peripheral neuropathic pain. Psychiatrists reported a high perceived efficacy of duloxetine: 94% rated it as \"more effective\" or \"much more effective\" for diabetic peripheral neuropathy, and 93% gave similarly positive ratings for general neuropathic pain. For somatization, 70% found it \"effective\" or \"very effective\", and 83% observed improvements in quality of life for many of their patients. Psychiatrists generally reported favorable perceptions of duloxetine's tolerability profile: 97.5% rated it as the antidepressant associated with the least weight gain, and 82.5% perceived fewer sexual side effects compared to other options. Sedation and gastrointestinal side effects were generally considered mild or less severe. In terms of treatment adherence, 69% rated it as \"better\" or \"much better\" than other antidepressants, and 80% found its combination with other antidepressants to be \"favorable\" or \"very favorable\". Overall satisfaction was high, with 99% of psychiatrists reporting being either \"satisfied\" or \"very satisfied\" with its use. The side effect profile was generally viewed as manageable, with low perceived rates of weight gain, sedation, and sexual dysfunction. Furthermore, 96% of respondents expressed a willingness to recommend duloxetine to their colleagues.</p><p><strong>Conclusions: </strong>Psychiatrists reported highly favorable attitudes toward duloxetine, viewing it as a flexible treatment option in routine care. However, these findings reflect clinicians' subjective perceptions rather than objective clinical outcomes and should be interpreted accordingly.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Non-Invasive Brain Stimulation for the Management of Chronic Musculoskeletal Pain: Fad or Future?","authors":"Philippe Patricio, Hugo Massé-Alarie","doi":"10.3390/brainsci15070760","DOIUrl":"10.3390/brainsci15070760","url":null,"abstract":"<p><p>This article aims to offer a broad perspective on the use of non-invasive brain stimulation (NIBS) techniques in the context of chronic musculoskeletal pain (CMP) conditions. While NIBS has demonstrated promising efficacy in certain chronic pain populations, its application in the management of CMP remains limited. This paper examines the current evidence supporting the use of NIBS for pain relief in CMP, the rationale and proposed mechanisms of action, the importance of patient selection, common methodological limitations in the existing literature, and the potential adverse effects of these techniques. The authors argue that the current evidence is insufficient to support widespread clinical adoption of NIBS for CMP. Advancing the field will require more rigorous study designs, with adequately powered and properly blinded randomized controlled trials. Additionally, future research should address the identification of potential responders to brain stimulation, conduct economic evaluations, and carefully assess the benefit-risk ratio before NIBS can be integrated into routine clinical practice.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating Exosomal microRNAs from Bench to Bedside in Parkinson's Disease.","authors":"Oscar Arias-Carrión, María Paulina Reyes-Mata, Joaquín Zúñiga, Daniel Ortuño-Sahagún","doi":"10.3390/brainsci15070756","DOIUrl":"10.3390/brainsci15070756","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, α-synuclein aggregation, and chronic neuroinflammation. Recent evidence suggests that exosomal microRNAs (miRNAs)-small, non-coding RNAs encapsulated in extracellular vesicles-are key regulators of PD pathophysiology and promising candidates for biomarker development and therapeutic intervention. Exosomes facilitate intercellular communication, cross the blood-brain barrier, and protect miRNAs from degradation, rendering them suitable for non-invasive diagnostics and targeted delivery. Specific exosomal miRNAs modulate neuroinflammatory cascades, oxidative stress, and synaptic dysfunction, and their altered expression in cerebrospinal fluid and plasma correlates with disease onset, severity, and progression. Despite their translational promise, challenges persist, including methodological variability in exosome isolation, miRNA profiling, and delivery strategies. This review integrates findings from preclinical models, patient-derived samples, and systems biology to delineate the functional impact of exosomal miRNAs in PD. We propose mechanistic hypotheses linking miRNA dysregulation to molecular pathogenesis and present an interactome model highlighting therapeutic nodes. Advancing exosomal miRNA research may transform the clinical management of PD by enabling earlier diagnosis, molecular stratification, and the development of disease-modifying therapies.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuromodulation Interventions for Language Deficits in Alzheimer's Disease: Update on Current Practice and Future Developments.","authors":"Fei Chen, Yuyan Nie, Chen Kuang","doi":"10.3390/brainsci15070754","DOIUrl":"10.3390/brainsci15070754","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive cognitive and language impairments that significantly impact communication and quality of life. Neuromodulation techniques, including repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS), have emerged as promising interventions. This study employs bibliometric analysis to evaluate global research trends in neuromodulation treatments for AD-related language impairments. A total of 88 publications from the Web of Science Core Collection (2006-2024) were analyzed using bibliometric methods. Key indicators such as publication trends, citation patterns, collaboration networks, and research themes were examined to map the intellectual landscape of this field. The analysis identified 580 authors across 65 journals, with an average of 34.82 citations per article. Nearly half of the publications were produced after 2021, indicating rapid recent growth. The findings highlight a predominant focus on non-invasive neuromodulation methods, particularly rTMS and tDCS, within neurosciences and neurology. While research activity is increasing, significant challenges persist, including ethical concerns, operational constraints, and the translational gap between research and clinical applications. This study provides insights into the current research landscape and future directions for neuromodulation in AD-related language impairments. The results emphasize the need for novel neuromodulation techniques and interdisciplinary collaboration to enhance therapeutic efficacy and clinical integration.</p>","PeriodicalId":9095,"journal":{"name":"Brain Sciences","volume":"15 7","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}